Att #7

[redacted]O-1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P-CJ 1192	SERIAL NO. 08/328,673
	APPLICANT Gregory et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE 10/25/94	GROUP ~~1806~~ 1636

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

BW		Aiello et al. "Adenovirus 5 DNA Sequences Present and RNA Sequences Transcribed in Transformed Human Embryo Kidney Cells (HEK-Ad-5 or 293) Virology 94:460-469 (1979).
BW		Aulitzky et al. "Recombinant Tumour Necrosis Factor Alpha Administered Subcutaneously or Intramuscularly for Treatment of Advanced Malignant Disease: a Phase I Trial." Eur. J. Cancer 27(4):462-467 (1991).
BW		Austin, E.A. and Huber, B.E. "A First Step in the Development of Gene Therapy for Colorectal Carcinoma: Cloning, Sequencing, and Expression of *Escherichia coli* Cytosine Deaminase." Eur. J. Cancer 27(4):462-467 (1991).
BW		Bacchetti, S. and Graham, F. "Inhibition of cell proliferation by an adenovirus vector expressing the human wild type p53 protein." International Journal of Oncology 3:781-788 (1993).
BW		Baker et al. "Suppression of Human Colrectal Carcinoma Cell Growth by Wild-Type p53." 249:912-915 (1990).
BW		Bartek et al. "Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies." Oncogene 6:1699-1703 (1991).
BW		Berkner, Kathleen L. and Sharp, Phillip A. "Effect of the tripartite leader on synthesis of a non-viral protein in an adenovirus 5 recombinant." Nucleic Acids Research 13(3):841-857 (1985).
BW		Boshart et al. "A Very Strong Enhancer Is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus." Cell 41:521-530 (1985).
BW		Bressac et al. "Abnormal structure and expression of p53 gene in human hepatocellular carcinoma." Proc. Natl. Acad. Sci. (USA) 87:1973-1977 (1990).
BW		Caruso et al. "Regression of established macroscopic liver metastases after *in situ* transfduction of a suicide gene." Proc. Natl. Acad. Sci. (USA) 90:7024-7028 (1993).

FORM PTO-1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P-CJ 1192	SERIAL NO. 08/328,673
	APPLICANT Gregory et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE 10/25/94	GROUP ~~1806~~ 1636

BW		Challberg, M.D. and Kelly, T.J. PNAS USA, 76:655-659 (1979).
BW		Chen et al. "Genetic Mechanisms of Tumor Suppression by the Human p53 Gene." Science 250:1576-1580 (1990).
BW		Chen et al. "Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate." Oncogene 6:1799-1805 (1991).
BW		Cheng et al. "Suppression of Acute Lymphoblastic Leukemia by the Human Wild-Type *p53* Gene." Cancer Research 52:222-226 (1992).
BW		Colby, W.W. and Shenk, T.J., "Adenovirus Type 5 Virions Can be Assembled in Vivo in the Absence of Detectable Polypeptide IX" Virology 39:977-980 (1981)
BW		Culver et al. "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors" Science 256:1550-1552 (1992).
BW		Culver et al. "Lymphocytes as a cellular vehicles for gene therapy in mouse and man." Proc. Natl. Acad. Sci. USA 88:3155-3159 (1991).
BW		Demetri et al. "A Phase I Trial of Recombinant Human Tumor Necrosis Factor and Interferon-Gamma: Effects of Combination Cytokine Administration In Vivo." J. Clin. Oncol. 7(10):1545-1553.
BW		Diller et al. "p53 Functions as a Cell Cycle Control Protein in Osteosarcomas." Mol. Cell. Biology 10:5772-5781 (1990).
BW		El-Deiry et al. "*WAF1*, a Potential Mediator of p53 Tumor Suppression." Cell 75:817-825 (1993).
BW		Ezzidine et al. "Selective Killing of Glioma Cells in Culture and in Vivo by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase Gene." The New Biologist 3:608-614 (1991).
BW		Feinstein et al. "Expression of the normal p53 gene induces differentiation of K562 cells." Oncogene 7:1853-1857 (1992).
BW		Freeman et al. "The "Bystander Effect": Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified." Cancer Res. 53:5274-5283 (1993).
BW		Ghosh-Choudhury et al. "Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes." EMBO Journal 6:1733-1739 (1987).
BW		Gooding et al. "Molecular Mechanisms by Which Adenoviruses Counteract Antiviral Immune Defenses." Crit. Rev. Immunol. 10:53-71 (1990).
BW		Graham, F.L. and van der Eb, A.J. "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA." Virology 52:456-467 (1973).
~~BW~~ BW ok		~~Graham, F.L. and Prevec, L. Vaccines: New Approaches to Immunological Problems. R.W. Ellis (ed.), Boston: Butterworth-Heinemann, 363-390 (1992).~~

FORM PTO-1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P-CJ 1192	SERIAL NO. 08/328,673
	APPLICANT Gregory et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE 10/25/94	GROUP ~~1806~~ 1636

BW		Heuvel et al. "Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells." EMBO Journal 9:2621-2629 (1990).
BW		Hock et al. "Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ." Proc. Natl. Acad. Sci. USA 90:2774-2778 (1992).
BW		Hollstein et al. "p53 Mutations in Human Cancers." Science 253:49-53 (1991).
BW		Horwitz, Marshall S. "Adenoviridae and Their Replication." sVirology B.N. Fields (ed.), New York: Raven Press, 1679-1721 (1990).
BW		Horvath, J. and Weber, J.M. "Nonpermissivity of Human Peripheral Blood Lymphocytes to Adenovirus Type 2 Infection." J. Virol. 62:341-345 (1988).
BW		Huang et al. "A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product." Nature 350:160-162 (1991).
BW		Huber et al. "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy." Proc. Natl. Acad. Sci. USA 88:8039-8043 (1991).
BW		Hunter, T. "Braking the Cycle." Cell 75:839-841 (1993).
BW		Jones, N. and Shenk, T. "Isolation of Adenovirus Type 5 Host Range Deletion Mutants Defective for Transformation of Rat Embryo Cells." Cell 17:683-689 (1979).
BW		Kamb et al. "A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types." Science 264:436-440 (1994).
BW		Kuerbitz et al. "Wild-type p53 is a cell cycle checkpoint determinant following irradiation." Proc. Natl. Acad. Sci. USA 89:7491-7495 (1992).
BW		Landmann et al. "Prolonged Interferon-γ Application by Subcutaneous Infusion in Cancer Patients: Differential Response of Serum CD14, Neopterin, and Monocyte HLA Class I and II Antigens." J. Interferon Res. 12(2):103-111 (1992).
BW		Lane, D.P. "p53, guardian of the genome." Nature 358:15-16 (1992).
BW		Lee et al. "Human Retinoblastoma Susceptibility Gene: Cloning, Identification, and Sequence." Science 235:1394-1399 (1987).
BW		Lemaistre et al. "Therapeutic effects of genetically engineered toxin (DAB_{486}IL-2) in patient with chronic lymphocytic leukaemia." Lancet 337:1124-1125 (1991).

FORM PTO-1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P-CJ 1192	SERIAL NO. 08/328,673
	APPLICANT Gregory et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE 10/25/94	GROUP ~~1806~~ 1636

BW		Lemarchand, Patricia. "Adenovirus-mediated transfer of a recombinant human α_1-antitrypsin cDNA to human endothelial cells." Proc. Natl. Acad. Sci. USA 89:6482-6486 (1992).
BW		Levine, A.J. "The Tumor Suppressor Genes." Annu. Rev. Biochem. 62:623-651 (1993).
BW		Lowe et al. "p53 is required for radiation-induced apoptosis in mouse thymocytes." Nature 362:847-852 (1993).
BW		Lowe et al. "p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents." Cell 74:957-967 (1993).
BW		Mercer, et al. "Negative growth regulation in a glioblastoma tumor cell ine that conditionally expresses human wild-type p53." Proc. Natl. Acad. Sci. USA 87:6166-6170 (1990).
BW		Metzger, Gerard and Werbin, Harold. "Evidence for *N*-Acetoxy-*N*-2-acetylaminofluorene Induced Covalent-like Binding of Some Nonhistone Proteins to DNA in Chromatin." Biochemistry 18(4):655-659 (1979).
BW		Moolten, F.C. "Tumor Chemosensitivity Conferred by Inserted Herpes Thymidine Kinase Genes: Paradigm for a Prospective Cancer Control Strategy." Cancer Res. 46:5276-5281 (1986).
BW		Nakabayashi et al. "Transcriptional Regulation of α-Fetoprotein Expression by Dexamethasone in Human Hepatoma Cells." The Journal of Biological Chemistry 264:266-271 (1989).
BW		Palmer et al. "Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes." Proc. Natl. Acad. Sci. USA 88:1330-1334 (1991).
BW		Rao et al. "The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins." Proc. Natl. Acad. Sci. USA 89:7742-7746 (1992).
BW		Ravoet et al. "Non-Surgical Treatment of Hepatocarcinoma." Journal of Surgical Oncology Supplement 3:104-111 (1993).
BW		Rich et al. "Development and Analysis of Recombinant Adenoviruses for Gene Therapy of cystic Fibrosis." Human Gene Therapy 4:461-476 (1993).
BW		Rosenfeld et al. "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium." Cell 68:143-155 (1992).
BW		Sarnow et al. "Adenovirus E1b-58kd Tumor Antigen and SV40 Large Tumor Antigen Are Physically Associated with the Same 54 kd Cellular Protein in Transformed Cells." Cell 28:387-394 (1982).
BW		Shaw et al. "Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line." Proc. Natl. Acad. Sci. USA 89:4495-4499 (1992).

FORM PTO-1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO. P-CJ 1192	SERIAL NO. 08/328,673
	APPLICANT Gregory et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE 10/25/94	GROUP ~~1806~~ 1636

BW	✓	Siegfried, W. "Perspectives in Gene Therapy with Recombinant Adenoviruses." Exp. Clin. Endocrinol. 101:7-11 (1993).
BW	✓	Sorscher et al. "Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines." Gene Therapy 1:233-238.
BW	✓	Spector, David J. "The Pattern of Integration of Viral DNA Sequences in the Adenovirus 5-Transformed Human Cell Line 293." Virology 130:533-538 (1983).
BW	✓	Stewart et al. "Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy." EMBO Journal 12:2589-2599 (1993).
BW	✓	Supersaxo et al. Pharm. Res. 5(8):472-476 (1988).
BW	✓	Straus, S.E. "Adenovirus infections in humans." The Adenoviruses. H.S. Ginsberg (ed.), New York: Plenum Press, 451-496 (1984).
BW	✓	Takahashi et al. "p53: A Frequent Target for Genetic Abnormalities in Lung Cancer." Science 246:491-494 (1989).
BW	✓	Takahashi et al. "Wild-type but not Mutant *p53* Suppresses the Growth of Human Lung Cancer Cells Bearing Multiple Genetic Lesions." Cancer Research 52:2340-2343 (1992).
BW	✓	Thimmappaya et al. "Adenovirus VAI RNA Is Required for Efficient Translation of Viral mRNAs at Late Times after Infection." Cell 31:543-551 (1982).
BW	✓	Wang et al. "Quantitation of mRNA by the polymerase chain reaction." Proc. Natl. Acad. Sci. USA 86:9717-9721 (1989).
BW	✓	Watanable et al. "Cell-specific Enhancer Activity in a Far Upstream Region of the Human α-Fetoprotein Gene." The Journal of Biological Chemistry 262:4812-4818 (1987).
BW	✓	White et al. "The 19-Kilodalton Adenovirus E1B Transforming Protein Inhibits Programmed Cell Death and Prevents Cytolysis by Tumor Necrosis Factor α." Mol. Cell. Biol. 12:2570-2580 (1992).
BW	✓	Wills et al. Human Gene Therapy 5:1079-1088 (1994).
BW	✓	Yonish-Rouach et al. "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6." Nature 352:345-347 (1991).

EXAMINER	DATE CONSIDERED
Bonnie D. Kelly	4/4/96

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.